349 related articles for article (PubMed ID: 35487087)
21. Capsaicin attenuates imiquimod-induced epidermal hyperplasia and cutaneous inflammation in a murine model of psoriasis.
Chan TC; Lee MS; Huang WC; Chang WY; Krueger JG; Tsai TF
Biomed Pharmacother; 2021 Sep; 141():111950. PubMed ID: 34328106
[TBL] [Abstract][Full Text] [Related]
22. Worsening of imiquimod-induced psoriasiform inflammation in mice by environmental pollutant, di-(2-ethylhexyl) phthalate through dysregulation in IL-17A and Nrf2/iNOS signaling in peripheral myeloid and CD4 + T cells.
Alfardan AS; Nadeem A; Ahmad SF; Al-Harbi NO; Alqinyah M; Attia SM; Sarawi W; Alanazi AZ; Alhazzani K; Ibrahim KE
Int Immunopharmacol; 2024 Jan; 126():111293. PubMed ID: 38056199
[TBL] [Abstract][Full Text] [Related]
23. Tranexamic acid improves psoriasis-like skin inflammation: Evidence from in vivo and in vitro studies.
Hseu JH; Chan CI; Vadivalagan C; Chen SJ; Yen HR; Hseu YC; Yang HL; Wu PY
Biomed Pharmacother; 2023 Oct; 166():115307. PubMed ID: 37573659
[TBL] [Abstract][Full Text] [Related]
24. Khasianine ameliorates psoriasis-like skin inflammation and represses TNF-α/NF-κB axis mediated transactivation of IL-17A and IL-33 in keratinocytes.
Yang Y; Zhang Y; Chen X; Su Z; Deng Y; Zhao Q
J Ethnopharmacol; 2022 Jun; 292():115124. PubMed ID: 35183690
[TBL] [Abstract][Full Text] [Related]
25. Imiquimod-induced psoriasis-like skin inflammation is suppressed by BET bromodomain inhibitor in mice through RORC/IL-17A pathway modulation.
Nadeem A; Al-Harbi NO; Al-Harbi MM; El-Sherbeeny AM; Ahmad SF; Siddiqui N; Ansari MA; Zoheir KM; Attia SM; Al-Hosaini KA; Al-Sharary SD
Pharmacol Res; 2015 Sep; 99():248-57. PubMed ID: 26149470
[TBL] [Abstract][Full Text] [Related]
26. FXYD3 enhances IL-17A signaling to promote psoriasis by competitively binding TRAF3 in keratinocytes.
Yang W; He R; Qu H; Lian W; Xue Y; Wang T; Lin W; Zhu P; Xia M; Lai L; Wang Q
Cell Mol Immunol; 2023 Mar; 20(3):292-304. PubMed ID: 36693922
[TBL] [Abstract][Full Text] [Related]
27. Selenium-Rich Yeast Peptide Fraction Ameliorates Imiquimod-Induced Psoriasis-like Dermatitis in Mice by Inhibiting Inflammation via MAPK and NF-κB Signaling Pathways.
Guo H; Li M; Liu H
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216231
[TBL] [Abstract][Full Text] [Related]
28. An alternative pathway of imiquimod-induced psoriasis-like skin inflammation in the absence of interleukin-17 receptor a signaling.
El Malki K; Karbach SH; Huppert J; Zayoud M; Reissig S; Schüler R; Nikolaev A; Karram K; Münzel T; Kuhlmann CR; Luhmann HJ; von Stebut E; Wörtge S; Kurschus FC; Waisman A
J Invest Dermatol; 2013 Feb; 133(2):441-51. PubMed ID: 22951726
[TBL] [Abstract][Full Text] [Related]
29. Interleukin-17 receptor D constitutes an alternative receptor for interleukin-17A important in psoriasis-like skin inflammation.
Su Y; Huang J; Zhao X; Lu H; Wang W; Yang XO; Shi Y; Wang X; Lai Y; Dong C
Sci Immunol; 2019 Jun; 4(36):. PubMed ID: 31175175
[TBL] [Abstract][Full Text] [Related]
30. Acitretin inhibits IL-17A-induced IL-36 expression in keratinocytes by down-regulating IκBζ.
Tu J; Yin Z; Guo J; He F; Long F; Yin Z
Int Immunopharmacol; 2020 Feb; 79():106045. PubMed ID: 31863918
[TBL] [Abstract][Full Text] [Related]
31. Protein Kinase CK2 Promotes Proliferation, Abnormal Differentiation, and Proinflammatory Cytokine Production of Keratinocytes via Regulation of STAT3 and Akt Pathways in Psoriasis.
Huang W; Zheng X; Huang Q; Weng D; Yao S; Zhou C; Li Q; Hu Y; Xu W; Huang K
Am J Pathol; 2023 May; 193(5):567-578. PubMed ID: 37080661
[TBL] [Abstract][Full Text] [Related]
32. NETs contribute to psoriasiform skin inflammation: A novel therapeutic approach targeting IL-36 cytokines by a small molecule tetrahydroxystilbene glucoside.
Zhan ZY; Jiang M; Zhang ZH; An YM; Wang XY; Wu YL; Nan JX; Lian LH
Phytomedicine; 2024 Aug; 131():155783. PubMed ID: 38838402
[TBL] [Abstract][Full Text] [Related]
33. An alkaloid-rich phytopharmaceutical prepared from Qing Dai against IL-17A-induced psoriasis.
Lee CL; Wang CM; Song YC; Liu CT; Chu MY; Yen HR
J Ethnopharmacol; 2024 Jan; 318(Pt A):116924. PubMed ID: 37454748
[TBL] [Abstract][Full Text] [Related]
34. Galectin-7 downregulation in lesional keratinocytes contributes to enhanced IL-17A signaling and skin pathology in psoriasis.
Chen HL; Lo CH; Huang CC; Lu MP; Hu PY; Chen CS; Chueh DY; Chen P; Lin TN; Lo YH; Hsiao YP; Hsu DK; Liu FT
J Clin Invest; 2021 Jan; 131(1):. PubMed ID: 33055419
[TBL] [Abstract][Full Text] [Related]
35. Programmed cell death ligand 1 alleviates psoriatic inflammation by suppressing IL-17A production from programmed cell death 1-high T cells.
Kim JH; Choi YJ; Lee BH; Song MY; Ban CY; Kim J; Park J; Kim SE; Kim TG; Park SH; Kim HP; Sung YC; Kim SC; Shin EC
J Allergy Clin Immunol; 2016 May; 137(5):1466-1476.e3. PubMed ID: 26824999
[TBL] [Abstract][Full Text] [Related]
36. Effect of γ-secretase inhibitor on Th17 cell differentiation and function of mouse psoriasis-like skin inflammation.
Ma L; Xue H; Qi R; Wang Y; Yuan L
J Transl Med; 2018 Mar; 16(1):59. PubMed ID: 29523162
[TBL] [Abstract][Full Text] [Related]
37. IL-17A/IL-17RA interaction blockade sensitizes synovial macrophages to efferocytosis and PD-L1 signaling via rewiring STAT-3/ADAM17/MERTK axis in rheumatoid arthritis animal model.
Samarpita S; Srivastava S; Srikanth M; Miriam Jose A; Rithvik A; Rasool M
Int Immunopharmacol; 2024 Jul; 136():112343. PubMed ID: 38810305
[TBL] [Abstract][Full Text] [Related]
38. Anti-Angiogenic Efficacy of PSORI-CM02 and the Associated Mechanism in Psoriasis
Lu Y; Yang Y; Zhang J; Zhang H; Ma C; Tang X; Wu J; Li L; Wei J; Chen H; Lu C; Han L
Front Immunol; 2021; 12():649591. PubMed ID: 33995368
[TBL] [Abstract][Full Text] [Related]
39. IL-17A exacerbates psoriasis in a STAT3 overexpressing mouse model.
Xie X; Zhang L; Lin Y; Liu X; Wang N; Li P
PeerJ; 2023; 11():e15727. PubMed ID: 37465147
[TBL] [Abstract][Full Text] [Related]
40. Bruton's tyrosine kinase inhibitor suppresses imiquimod-induced psoriasis-like inflammation in mice through regulation of IL-23/IL-17A in innate immune cells.
Nadeem A; Ahmad SF; Al-Harbi NO; El-Sherbeeny AM; Alasmari AF; Alanazi WA; Alasmari F; Ibrahim KE; Al-Harbi MM; Bakheet SA; Attia SM
Int Immunopharmacol; 2020 Mar; 80():106215. PubMed ID: 31982823
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
